Join us for the Arrowhead Cardiometabolic Virtual Investor & Analyst Event, featuring key opinion leaders, Christie Ballantyne, M.D., (Baylor College of Medicine) and Robert Rosenson, M.D. (Icahn School of Medicine at Mount Sinai), who will discuss the Phase 2 data presented on the Company’s investigational cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, in late-breaking oral presentations at AHA, as well as the Company’s plans for future clinical development of these promising product candidates  The discussion will highlight the potential of ARO-APOC3 and ARO-ANG3 to address lipids and lipoproteins that may contribute to the substantial residual risk of cardiovascular disease that may remain after low density lipoprotein cholesterol (LDL-C) is treated using existing therapies available.

Additionally, the current treatment landscape for various lipid disorders with unmet medical need will be highlighted.

A live question and answer session will follow.